CN113545459A - Composition with function of increasing bone mineral density and health-care product for increasing bone mineral density - Google Patents
Composition with function of increasing bone mineral density and health-care product for increasing bone mineral density Download PDFInfo
- Publication number
- CN113545459A CN113545459A CN202010333088.4A CN202010333088A CN113545459A CN 113545459 A CN113545459 A CN 113545459A CN 202010333088 A CN202010333088 A CN 202010333088A CN 113545459 A CN113545459 A CN 113545459A
- Authority
- CN
- China
- Prior art keywords
- parts
- calcium
- bone density
- weight
- increasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001965 increasing effect Effects 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 210000000988 bone and bone Anatomy 0.000 title abstract description 19
- 229910052500 inorganic mineral Inorganic materials 0.000 title abstract description 15
- 239000011707 mineral Substances 0.000 title abstract description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 78
- 230000037182 bone density Effects 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 41
- 241000234282 Allium Species 0.000 claims abstract description 28
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 28
- 229940034055 calcium aspartate Drugs 0.000 claims abstract description 28
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 claims abstract description 26
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 17
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims description 29
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical group C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims description 19
- 240000003394 Malpighia glabra Species 0.000 claims description 19
- 235000014837 Malpighia glabra Nutrition 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000005913 Maltodextrin Substances 0.000 claims description 14
- 229920002774 Maltodextrin Polymers 0.000 claims description 14
- 229940035034 maltodextrin Drugs 0.000 claims description 14
- 239000004386 Erythritol Substances 0.000 claims description 11
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 11
- 239000004376 Sucralose Substances 0.000 claims description 11
- 235000019414 erythritol Nutrition 0.000 claims description 11
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical group OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 11
- 229940009714 erythritol Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical group O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 11
- 235000019408 sucralose Nutrition 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 241000167854 Bourreria succulenta Species 0.000 claims description 8
- 235000019693 cherries Nutrition 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 235000019640 taste Nutrition 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 50
- 239000011575 calcium Substances 0.000 abstract description 50
- 229910052791 calcium Inorganic materials 0.000 abstract description 50
- 239000000047 product Substances 0.000 abstract description 32
- 238000010521 absorption reaction Methods 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 11
- 229940069978 calcium supplement Drugs 0.000 abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 24
- 208000001132 Osteoporosis Diseases 0.000 description 16
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 229930003268 Vitamin C Natural products 0.000 description 12
- 235000019154 vitamin C Nutrition 0.000 description 12
- 239000011718 vitamin C Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 10
- 235000013305 food Nutrition 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 3
- 208000029725 Metabolic bone disease Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 description 2
- 244000298697 Actinidia deliciosa Species 0.000 description 2
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- HBYOLNPZXLHVQA-UHFFFAOYSA-J dicalcium dicarbonate Chemical compound [Ca+2].[Ca+2].[O-]C([O-])=O.[O-]C([O-])=O HBYOLNPZXLHVQA-UHFFFAOYSA-J 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000020604 functional milk Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition with a bone density increasing function and a health-care product with the bone density increasing function, wherein the composition with the bone density increasing function comprises the following components in parts by mass: 5 to 20 portions of calcium aspartate, 0.2 to 0.4 portion of onion powder, 1 to 3 portions of citric acid and 5 to 20 portions of antioxidant. The composition with the function of increasing the bone mineral density selects calcium aspartate as a calcium source, onion powder is added to promote the absorption of calcium and the increase of the bone mineral density, and citric acid is added to further promote the absorption of calcium. As can be seen in the section of the examples, the composition for increasing bone density of the present invention has a better calcium absorption effect than the conventional calcium supplement.
Description
Technical Field
The invention relates to the field of health-care food, in particular to a composition with a function of increasing bone mineral density and a health-care product for increasing bone mineral density.
Background
Osteoporosis is a systemic skeletal disease characterized by osteopenia, destruction of the delicate structure of bone tissue, increased bone fragility, and increased risk of fracture. It can fracture bones at any position except the skull. Osteoporosis and osteopenia are common metabolic bone diseases even in developed countries due to aging of the world population. The medical community has put the prevention and treatment of osteoporosis, the prevention of fracture, the treatment of hyperlipidemia, the prevention of myocardial infarction, the treatment of hypertension and the prevention of stroke in the same important positions. According to incomplete statistics, the incidence rate of osteoporosis of old people over 60 years old in China is about 59.89%, and increasing bone density and effectively treating osteoporosis become important subjects which are widely concerned by people. Osteoporosis is a worldwide health problem that is becoming more and more appreciated by people. At present, about 2 hundred million people all over the world suffer from osteoporosis, and the incidence rate thereof is leaped to the seventh of common diseases and frequently encountered diseases. Recent studies have shown that osteoporosis, which has been regarded as a unique disease of the elderly in China, actually exists in childhood. So far, no safe and effective method is available to completely restore normal bone mass and structure of the loosened bone, so that it is important to improve the understanding of people on the risk of osteoporosis, understand the pathogenic factors of osteoporosis and strengthen early prevention. In order to prevent or reduce the occurrence of the disease, it is necessary to take certain intervention measures in addition to enhancing self-care consciousness and making efforts to develop good living habits. The health food has certain health care function, high safety and long-term taking, and can meet the daily health care requirement of people, so the development of the health food for increasing the bone mineral density has wide application prospect. The product can remarkably reduce the current induction factors of osteoporosis diseases with high morbidity, wide morbidity population and serious influence on human health and life quality while increasing the bone density, and can greatly enhance the significance and value of early prevention of osteoporosis.
Basic measures for osteoporosis include: 1) a balanced diet rich in calcium, low salt and appropriate amount of protein; 2) A calcium supplement preparation. The national academy of nutrition establishes a recommended daily calcium intake of 800mg (elemental calcium) for adults, and 1000mg for postmenopausal women and the elderly. The average amount of calcium obtained from diet by the elderly in China is about 400mg per day, so the average amount of element calcium to be supplemented per day is 500-600 mg.
However, conventional calcium supplement formulations tend to place more importance on the calcium content and have relatively less concern with respect to calcium absorption.
Disclosure of Invention
Based on this, the object of the present invention is to provide a composition having a function of increasing bone density; another object is to provide a health product for increasing bone density.
The composition for increasing the bone density function comprises the following components in parts by weight: 5 to 20 portions of calcium aspartate, 0.2 to 0.4 portion of onion powder, 1 to 3 portions of citric acid and 5 to 20 portions of antioxidant.
The health product for increasing the bone density comprises the following components in parts by mass: 5 to 20 portions of calcium aspartate, 0.2 to 0.4 portion of onion powder, 1 to 3 portions of citric acid, 5 to 20 portions of antioxidant, 15 to 40 portions of taste improving agent, 20 to 80 portions of carrier, 0.1 to 0.5 portion of anticaking agent and 0.02 to 0.2 portion of sweetener.
The composition with the function of increasing the bone mineral density selects calcium aspartate as a calcium source, onion powder is added to promote the absorption of calcium and the increase of the bone mineral density, and citric acid is added to further promote the absorption of calcium. As can be seen in the section of the examples, the composition for increasing bone density of the present invention has a better calcium absorption effect than the conventional calcium supplement.
Detailed Description
The technical solutions in the embodiments of the present invention will be described clearly and completely below, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be obtained by a person skilled in the art without any inventive step based on the embodiments of the present invention, are within the scope of the present invention.
The invention discloses a composition with a function of increasing bone density, which comprises the following components in parts by weight: 5 to 20 portions of calcium aspartate, 0.2 to 0.4 portion of onion powder, 1 to 3 portions of citric acid and 5 to 20 portions of antioxidant.
The calcium L-aspartate is used as a calcium source and is implemented according to the relevant regulation of the food nutrition enhancer use health standard (the implementation standard GB29226-2012 made by Baitai san Asia participation) in China.
The L-calcium aspartate can stably enter small intestine through stomach and be absorbed by human body, and the molecular structure of the L-calcium aspartate is similar to dipeptide protein calcium in natural food and is easy to be absorbed by intestinal tract.
The onion contains certain calcium, and Swiss scientists find that the bone density of experimental rats can be improved by eating the onion frequently, and the prevention and treatment of osteoporosis are facilitated.
Citric acid can promote digestion and absorption of calcium in vivo.
The composition with the function of increasing the bone mineral density selects calcium aspartate as a calcium source, onion powder is added to promote the absorption of calcium and the increase of the bone mineral density, and citric acid is added to further promote the absorption of calcium. As can be seen in the section of the examples, the composition for increasing bone density of the present invention has a better calcium absorption effect than the conventional calcium supplement.
Preferably, the weight portion of the calcium aspartate is 8 to 16, the weight portion of the onion powder is 0.22 to 0.3, the weight portion of the citric acid is 1.2 to 2, and the weight portion of the antioxidant is 8 to 16.
In a specific embodiment, the weight portion of the calcium aspartate is 9, 10, 11 or 12, the weight portion of the onion powder is 0.23, 0.24, 0.25, 0.26, 0.27 or 0.28, the weight portion of the citric acid is 1.3, 1.4, 1.5, 1.6, 1.7 or 1.8, and the weight portion of the antioxidant is 8.8, 9.8, 10.8 or 11.8.
Preferably, the antioxidant is acerola concentrated powder.
Acerola is rich in vitamin C, and is the most abundant fruit known in the world. The VC content in 100 g of acerola cherry fruits reaches 2445 mg, which is far higher than 40mg of lemon, 68mg of citrus and 100mg of kiwi, while guava which is always considered to have extremely high vitamin C content is only 180mg, which is worthy of the name of the king of vitamin C. Vitamin C is a good antioxidant and can scavenge free radicals generated during human activities.
In addition, acerola cherry also contains various nutrient substances such as vitamin A, B1, B2, E, P, nicotinic acid, anti-aging factor (SOD), calcium, iron, zinc, potassium, protein and the like, has extremely high nutritional value and is good reputation of life fruits. Wherein the vitamin P can prevent the vitamin C from being damaged by oxidation, and enhance the absorption and utilization effects of the vitamin C.
The composition with the function of increasing the bone density has the function of increasing the bone density, and is applied to preparing products for preventing or reducing osteoporosis or related diseases. The active ingredients for increasing bone density according to the present invention are commercially available or prepared according to the properties of each active ingredient.
The composition with the function of increasing the bone density can be applied to various calcium supplement products, and the application of the composition to solid health care products for increasing the bone density is described as an example below.
The health-care product for increasing the bone density comprises the following components in parts by mass: 5 to 20 portions of calcium aspartate, 0.2 to 0.4 portion of onion powder, 1 to 3 portions of citric acid, 5 to 20 portions of antioxidant, 15 to 40 portions of taste improving agent, 20 to 80 portions of carrier, 0.1 to 0.5 portion of anticaking agent and 0.02 to 0.2 portion of sweetener.
The calcium L-aspartate is used as a calcium source and is implemented according to the relevant regulation of the food nutrition enhancer use health standard (the implementation standard GB29226-2012 made by Baitai san Asia participation) in China.
The L-calcium aspartate can stably enter small intestine through stomach and be absorbed by human body, and the molecular structure of the L-calcium aspartate is similar to dipeptide protein calcium in natural food and is easy to be absorbed by intestinal tract.
The onion contains certain calcium, and Swiss scientists find that the bone density of experimental rats can be improved by eating the onion frequently, and the prevention and treatment of osteoporosis are facilitated.
Citric acid can promote digestion and absorption of calcium in vivo.
The health product for increasing the bone density selects calcium aspartate as a calcium source, onion powder is added to promote the absorption of calcium and the increase of the bone density, and citric acid is added to further promote the absorption of calcium. As can be seen from the description of the embodiments, the composition for increasing bone density according to the present invention has a better calcium absorption effect than the conventional calcium supplement.
Preferably, the weight portion of the calcium aspartate is 8 to 16, the weight portion of the onion powder is 0.22 to 0.3, and the weight portion of the citric acid is 1.2 to 2.
Specifically, the weight parts of the calcium aspartate are 9 parts, 10 parts, 11 parts or 12 parts, the weight parts of the onion powder are 0.23 part, 0.24 part, 0.25 part, 0.26 part, 0.27 part or 0.28 part, and the weight parts of the citric acid are 1.3 part, 1.4 part, 1.5 part, 1.6 part, 1.7 part or 1.8 parts.
In the health product for increasing bone density of the present embodiment, the total amount of each component is 100 parts.
Preferably, the antioxidant is acerola concentrated powder, and the acerola concentrated powder is 8-16 parts by weight.
Acerola is rich in vitamin C, and is the most abundant fruit known in the world. The VC content in 100 g of acerola cherry fruits reaches 2445 mg, which is far higher than 40mg of lemon, 68mg of citrus and 100mg of kiwi, while guava which is always considered to have extremely high vitamin C content is only 180mg, which is worthy of the name of the king of vitamin C. Vitamin C is a good antioxidant and can scavenge free radicals generated during human activities.
In addition, acerola cherry also contains various nutrient substances such as vitamin A, B1, B2, E, P, nicotinic acid, anti-aging factor (SOD), calcium, iron, zinc, potassium, protein and the like, has extremely high nutritional value and is good reputation of life fruits. Wherein the vitamin P can prevent the vitamin C from being damaged by oxidation, and enhance the absorption and utilization effects of the vitamin C.
Preferably, the taste improving agent is erythritol, and the mass portion of the erythritol is 20 to 35.
The erythritol can enhance natural fruity indexes and bring cool mouthfeel, the retention period of the product using the erythritol is longer, and the product can reduce the heat by about 65%.
Preferably, the carrier is maltodextrin, and the mass part of the maltodextrin is 45-60 parts.
The maltodextrin is used for improving the structure and the appearance of food, is applied to solid food, can ensure that the product does not stick teeth and leave residues in the mouth, has clear, smooth and full shape and appearance, reduces defective products and prolongs the shelf life of the product.
When the maltodextrin is used for solid beverages, the maltodextrin can keep the characteristics and the flavor of the original product, the cost is reduced, the product has mellow and fine mouthfeel, the flavor is rich, the instant effect is excellent, and the crystallization is inhibited; in addition, the maltodextrin has good emulsifying effect and obvious carrier effect.
When used for preparing functional food, the maltodextrin is easy to be absorbed by human body, and can be used in functional milk powder for athletes, patients, infants, etc., such as sucrose-free milk powder and sports beverage. The product has expanded volume, no caking, instant dissolution, good dissolvability, and increased nutrition ratio.
Preferably, the anticaking agent is silicon dioxide, and the mass part of the silicon dioxide is 0.2-0.35 part.
Preferably, the sweetening agent is sucralose, and the mass part of the sucralose is 0.04 to 0.1 part.
Sucralose as a sweetener has the following advantages:
1) the sweetness is high, which is 600-650 times of that of cane sugar;
2) the taste is pure, no peculiar smell or bitter taste exists, the sweet characteristic curve almost overlaps with the sucrose, which is incomparable with any other sweeteners;
3) absolute safety, ADI value of 15mg/kg, no question about safety and toxicology;
4) the calorie value is extremely low (can be regarded as 0), can not cause obesity, can be used for diabetic, cardiovascular and cerebrovascular disease patient and old person;
5) the product has good solubility and stability, acid and alkali resistance, high temperature resistance and long shelf life; the sweet taste of the food can be realized from acidity to neutrality, and the sour taste and the salty taste are lightened; has masking effect on astringent taste, bitter taste, alcoholic taste, etc.; has synergistic effect on spicy taste and milk taste, and has wide application range.
In a specific embodiment, the acerola concentrated powder is 8.8 parts, 9.8 parts, 10.8 parts or 11.8 parts by weight.
In a specific embodiment, the erythritol is present in an amount of 22, 23, 24, 25, 26, 27, or 28 parts by weight.
In a particular embodiment, the maltodextrin is present in an amount of 50.11 parts, 51.11 parts, 52.11 parts, 53.11 parts, 54.11 parts, 55.11 parts, or 56.11 parts by weight.
In a particular embodiment, the silica is present in a mass fraction of 0.24 parts, 0.26 parts, 0.28 parts, 0.30 parts, 0.32 parts, or 0.34 parts.
In a specific embodiment, the sucralose is present in an amount of 0.05 parts, 0.06 parts, 0.07 parts, 0.08 parts, or 0.09 parts by weight.
Specifically, the health product for increasing the bone density disclosed by the invention is an oral preparation. The oral preparation includes hard capsule, soft capsule, granule, tablet, oral liquid, bagged tea, beverage and powder.
Preferably, the health product for increasing the bone density further comprises auxiliary materials.
The preparation process of the health product for increasing bone density comprises sieving calcium aspartate, onion powder, citric acid, and concentrated powder of acerola cherry, adding pharmaceutically acceptable adjuvants, mixing, and making into desired oral preparation by conventional method.
Specifically, the preparation method of the tablet comprises the steps of respectively sieving calcium aspartate, onion powder, citric acid and acerola concentrated powder with a 80-mesh sieve, adding a filler, mixing, adding a wetting agent, granulating, drying, granulating, adding a lubricant, mixing, tabletting, coating and subpackaging to obtain the tablet.
The following are specific examples
Example 1
The weight parts of the total weight parts of the paste are 100 parts, wherein the weight parts of the calcium aspartate, the onion powder are 0.23 part, the citric acid is 1.3 parts, the acerola concentrated powder is 8.8 parts, the erythritol is 22 parts, the silicon dioxide is 0.24 part, the sucralose is 0.05 part and the balance of maltodextrin.
Mixing the above materials, and making into solid health product for increasing bone density.
Example 2
The weight parts of the total weight parts of the paste are 100 parts, wherein the weight parts of the calcium aspartate, the onion powder are 0.28 part, the citric acid is 1.8 part, the acerola concentrated powder is 11.8 parts, the erythritol is 28 parts, the silicon dioxide is 0.34 part, the sucralose is 0.09 part and the balance of maltodextrin.
Mixing the above materials, and making into solid health product for increasing bone density.
Example 3
The weight parts of the total weight parts of the paste are 100 parts, wherein the weight parts of the calcium aspartate, the onion powder are 0.25 part, the citric acid is 1.5 parts, the acerola concentrated powder is 9.8 parts, the erythritol is 25 parts, the silicon dioxide is 0.28 part, the sucralose is 0.06 part, and the balance of the maltodextrin is used.
Mixing the above materials, and making into solid health product for increasing bone density.
Test example: calcium absorption test in rats
1. The test method comprises the following steps:
after one week of adaptation period, weaning rats born for 4 weeks were fasted for 12 hours and weighed, and immediately divided into groups of 10 rats each, and the rats were raised in cages. Deionized water was consumed during the feeding process to avoid calcium pick-up from the drinking water. Each group was dosed to the samples for 3 months according to the dosing design. Body weight and body length were recorded weekly for each group of animals.
2. Selecting the dosage:
the dosage of the calcium supplement liquid is 1 time per day and 5g/60kg BW per time when the calcium supplement liquid is taken by adults (the weight is measured by 60 kg).
According to the equivalent dose ratio of 6.17 calculated by the body surface area between human and animals, the dose of the experiment is set to be 0.24g/kg BW, and a blank control group (only basic feed is fed) and a calcium carbonate control group (the calcium carbonate dose is the same as the calcium level of the experimental group) are additionally arranged.
3. Sample preparation:
according to the experimental dosage design requirement, the health care products for increasing the bone mineral density prepared in the examples 1 to 3 are respectively taken, and the intragastric administration amount of each group is adjusted according to the calcium content of the health care products. The basal feed group is given basal feed and simultaneously is given distilled water for intragastric administration every day; the calcium carbonate control group is prepared by dissolving calcium carbonate in distilled water to 100mL to prepare suspension, and the test substance is given by adopting an oral gavage mode, and the gavage amount is weighed and adjusted every week.
4. Calcium absorption test: weaning rats at four weeks of birth were housed in cages for 4 weeks. Body length and body weight were measured once a week. Calcium metabolism experiments were performed 3 days after experiment 3 weeks. The food intake of 3 days is recorded, feces are collected for 72 hours, and the calcium content in the feed and the feces is measured. Uniformly mixing feed samples and sieving the feed samples by a 20-mesh sieve; drying the rat manure sample in a drying oven at 105 ℃, cooling in a dryer, and grinding. Care was taken to prevent contamination during sample preparation. Accurately weighing a certain amount of dried and ground sample, placing the sample in a 150mL triangular flask, covering the flask with a small funnel, adding 15mL mixed acid (nitric acid: perchloric acid is 4: 1), heating and digesting on an electric hot plate until white smoke is emitted, and the sample is transparent and colorless. When the acid solution is not enough, a small amount of mixed acid can be added. Adding several milliliters of deionized water after the digestive liquid is transparent and colorless, boiling to remove the residual acid, repeating twice, and finally ensuring that the volume of the digestive liquid is not more than 1 mL. When the sample is digested, a blank test is carried out at the same time, and mixed acid with the same volume as that of the sample is added and digested under the same conditions. The procedure was followed in the atomic absorption spectrophotometer instructions. The measured solution, the standard solution and the blank are all diluted by 0.5 percent lanthanum oxide solution, and the volume is determined.
Calculated according to the following formula: the apparent absorption rate of calcium is (calcium intake-calcium faecalis)/calcium intake x 100%.
After three months, the relevant experimental results and calculations were obtained as shown in table 1 below.
Table 1: calcium absorption test results in rats
| Number of rats (only) | Calcium intake (mg/d) | Calcium dung (mg/d) | Apparent absorption (%) | |
| Example 1 | 10 | 52.6±4.8 | 0.64±0.12** | 0.96±0.35 |
| Example 2 | 10 | 57.3±3.0 | 0.71±0.14** | 1.23±0.36 |
| Example 3 | 10 | 64.3±4.1 | 0.77±0.15** | 1.40±0.53 |
| Blank control group | 10 | 48.2±2.9 | 0.57±0.15** | 0.77±0.25 |
| Calcium carbonate control group | 10 | 62.2±4.5 | 1.58±0.52 | 2.49±0.73 |
P <0.05/p <0.01 for the low calcium control and the dosed group, respectively, compared to the calcium carbonate control group.
As can be seen from Table 1, after the health care products with the function of increasing bone density, prepared in examples 1-3, are orally administered to rats for 3 months, the apparent absorption rate of calcium of the rats in the low, medium and high groups in the examples is obviously higher than that of the calcium carbonate control group and slightly higher than that of the blank control group, and the difference is significant (p is less than 0.05). Therefore, the health care product with the function of increasing the bone mineral density, which is prepared by the low, medium and high groups of the embodiment, is remarkably superior to the traditional calcium carbonate calcium supplement product in the aspect of calcium absorption, has higher calcium absorption rate than that of the conventional food, and has better calcium absorption effect.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the claims. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. The composition for increasing the bone density function is characterized by comprising the following components in parts by weight: 5 to 20 portions of calcium aspartate, 0.2 to 0.4 portion of onion powder, 1 to 3 portions of citric acid and 5 to 20 portions of antioxidant.
2. The composition for increasing bone density function according to claim 1, wherein the calcium aspartate is 8 to 16 parts by mass, the onion powder is 0.22 to 0.3 part by mass, the citric acid is 1.2 to 2 parts by mass, and the antioxidant is 8 to 16 parts by mass.
3. The composition for increasing bone density function according to claim 2, wherein the calcium aspartate is 9 parts, 10 parts, 11 parts or 12 parts by weight, the onion powder is 0.23 part, 0.24 part, 0.25 part, 0.26 part, 0.27 part or 0.28 part by weight, the citric acid is 1.3 part, 1.4 part, 1.5 part, 1.6 part, 1.7 part or 1.8 part by weight, the antioxidant is 8.8 parts, 9.8 parts, 10.8 parts or 11.8 parts by weight, and the antioxidant is acerola concentrated powder.
4. The health product for increasing the bone density is characterized by comprising the following components in parts by mass: 5 to 20 portions of calcium aspartate, 0.2 to 0.4 portion of onion powder, 1 to 3 portions of citric acid, 5 to 20 portions of antioxidant, 15 to 40 portions of taste improving agent, 20 to 80 portions of carrier, 0.1 to 0.5 portion of anticaking agent and 0.02 to 0.2 portion of sweetener.
5. The health product for increasing bone density according to claim 4, wherein the calcium aspartate is 8 to 16 parts by weight, the onion powder is 0.22 to 0.3 part by weight, and the citric acid is 1.2 to 2 parts by weight.
6. The health product for increasing bone density according to claim 5, wherein the calcium aspartate is 9 parts, 10 parts, 11 parts or 12 parts by weight, the onion powder is 0.23 part, 0.24 part, 0.25 part, 0.26 part, 0.27 part or 0.28 part by weight, and the citric acid is 1.3 part, 1.4 part, 1.5 part, 1.6 part, 1.7 part or 1.8 part by weight.
7. The composition with the function of increasing bone density according to any one of claims 4 to 6, wherein the total parts of the components in the health product for increasing bone density is 100 parts;
the antioxidant is acerola cherry concentrated powder, and the acerola cherry concentrated powder accounts for 8-16 parts by weight;
the taste improver is erythritol, and the mass portion of the erythritol is 20-35 parts;
the carrier is maltodextrin, and the mass part of the maltodextrin is 45-60 parts;
the anticaking agent is silicon dioxide, and the mass portion of the silicon dioxide is 0.2-0.35;
the sweetener is sucralose, and the mass part of the sucralose is 0.04 to 0.1 part of the sucralose.
8. The health product for increasing bone density according to claim 7, wherein the acerola cherry concentrated powder is 8.8 parts, 9.8 parts, 10.8 parts or 11.8 parts by weight;
the mass portion of the erythritol is 22, 23, 24, 25, 26, 27 or 28;
the mass parts of the maltodextrin are 50.11 parts, 51.11 parts, 52.11 parts, 53.11 parts, 54.11 parts, 55.11 parts or 56.11 parts;
the mass portion of the silicon dioxide is 0.24 portion, 0.26 portion, 0.28 portion, 0.30 portion, 0.32 portion or 0.34 portion;
the mass portion of the sucralose is 0.05 portion, 0.06 portion, 0.07 portion, 0.08 portion or 0.09 portion.
9. The health product for increasing bone density according to claim 4, wherein the health product for increasing bone density is an oral preparation, and the oral preparation comprises hard capsules, soft capsules, granules, tablets, oral liquid preparations, bagged tea, beverages and powder.
10. The bone density increasing health product of claim 9, wherein the bone density increasing health product further comprises an auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010333088.4A CN113545459A (en) | 2020-04-24 | 2020-04-24 | Composition with function of increasing bone mineral density and health-care product for increasing bone mineral density |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010333088.4A CN113545459A (en) | 2020-04-24 | 2020-04-24 | Composition with function of increasing bone mineral density and health-care product for increasing bone mineral density |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113545459A true CN113545459A (en) | 2021-10-26 |
Family
ID=78129684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010333088.4A Pending CN113545459A (en) | 2020-04-24 | 2020-04-24 | Composition with function of increasing bone mineral density and health-care product for increasing bone mineral density |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113545459A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107296879A (en) * | 2017-06-23 | 2017-10-27 | 张岐山 | It is a kind of to increase the composition and preparation method of bone density preventing bone rarefaction |
| CN109156829A (en) * | 2018-09-12 | 2019-01-08 | 广州市顺芝堂生物科技有限公司 | A kind of Isin glue collagen composition and its preparation method and application |
-
2020
- 2020-04-24 CN CN202010333088.4A patent/CN113545459A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107296879A (en) * | 2017-06-23 | 2017-10-27 | 张岐山 | It is a kind of to increase the composition and preparation method of bone density preventing bone rarefaction |
| CN109156829A (en) * | 2018-09-12 | 2019-01-08 | 广州市顺芝堂生物科技有限公司 | A kind of Isin glue collagen composition and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5705898B2 (en) | Liver function improving agent | |
| JP6345243B2 (en) | Enbu fermented food or beverage composition | |
| EP2303297B1 (en) | Water-soluble extracts of artemisia dracunculus (tarragon) for improvement of glucose metabolism | |
| CN112120204A (en) | Sweet composition for reducing blood fat and preparation method thereof | |
| CN111032037A (en) | Compositions containing kaempferol analogs | |
| KR101018061B1 (en) | Jujube jam and manufacturing method thereof | |
| TWI225789B (en) | Compositions inhibiting muscle atrophy | |
| KR101212706B1 (en) | Production method of anti-obesity beverage using seaweed extracts | |
| JP4575588B2 (en) | A sickness / hangover prevention agent | |
| CN113545459A (en) | Composition with function of increasing bone mineral density and health-care product for increasing bone mineral density | |
| JP6755039B2 (en) | Preventing or improving hangover, liver function improving agent | |
| CN110856549A (en) | Sugar-free functional food and preparation method thereof | |
| KR101210748B1 (en) | Composition comprising the extract of Acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
| JP2008531552A (en) | Mixed herbal extract of ripening yellow and five peels and composition for prevention and treatment of osteoporosis containing the same as an active ingredient | |
| CN114794478A (en) | Composition capable of reducing blood pressure, blood fat and blood sugar and application thereof | |
| KR20140017933A (en) | Composition comprising fermented extract of trifoliate orange for improving diabetes | |
| CN110710672A (en) | Natural plant active calcium preparation and preparation method thereof | |
| JP2003265151A (en) | Tea for health | |
| CN107361281B (en) | Momordica grosvenori effervescent tablet and preparation method thereof | |
| CN110800893A (en) | Sucrose-free beverage with effects of reducing blood fat, reducing weight, promoting digestion, clearing heat, tonifying spleen, promoting diuresis and reducing blood sugar and preparation method thereof | |
| CN110856516A (en) | Sugar-free coffee functional food and preparation method thereof | |
| JP2003327539A (en) | Oral dose composition | |
| CN110856550A (en) | Sugar-free functional food and preparation method thereof | |
| JP4524018B2 (en) | Pharmaceutical composition and health food for prevention and treatment of non-insulin dependent diabetes mellitus comprising mulberry leaf and agaricus extract mixture | |
| KR102490355B1 (en) | Composition for preventing, improving or treating obesity comprising bile extract with increased taurochenodeoxycholic acid as an active ingredient and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |